Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug
PureTech Health spinout Celea Therapeutics will apply the financing toward a Phase 3 test of…
Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug
PureTech Health spinout Celea Therapeutics will apply the financing toward a Phase 3 test of its idiopathic pulmonary (IPF) drug, deupirfenidone. The pivotal study will test the oral small molecule head-to-head against a standard of care IPF drug. The post Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug appeared first on MedCity…
Modernizing Program Integrity in Medicaid Self-Directed Care
States must rethink how program integrity is designed and delivered by focusing on four key priorities that enable oversight to scale alongside these programs. The post Modernizing Program Integrity in Medicaid Self-Directed Care appeared first on MedCity News.
AI in Mental Health: Why Clinicians Need to Be in the Room
As clinicians, we learn not to be agreeable, we learn to challenge and sit in discomfort. We ask the hard questions underneath the one being asked. That is the work these tools are not yet built to do. The post AI in Mental Health: Why Clinicians Need to Be in the Room appeared first on…
When Evidence Gap Becomes a Commercial Liability
The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage. The post When Evidence Gap Becomes a Commercial Liability appeared first on MedCity News.
Journalists Discuss Healthcare Costs’ Political Fallout, Concerns About Canceled ICE Facility
KFF Health News senior correspondent Julie Appleby discussed the high cost of healthcare and the political fallout on WAMU’s 1A on June 30. Click here to hear Appleby on 1A. KFF Health News senior correspondent Renuka Rayasam discussed the public health concerns around a planned immigration detention center in Georgia on WUGA’s The Georgia Health…
July 4, 1862
By MIKE MAGEE When I asked my brilliant literary agent, Jill Kneerim, when I would know that my book proposal was ready for submission, she replied directly, “It will be ready when I say it is ready.” Eleven months later, in April, 2018, she finally green lit the project, and two weeks after that, in…
This Ear-Based Device Could Save Patients from Brain Bleed Complications
Aurenar’s V-Link, a non-invasive nerve stimulation device for preventing brain hemorrhage complications, just won FDA breakthrough device designation after early trials showed it cut cerebral vasospasm by more than 40%. The post This Ear-Based Device Could Save Patients from Brain Bleed Complications appeared first on MedCity News.
Color Broadens Cancer Expert Medical Opinion Program
Color expanded its Expert Medical Opinion program with a new peer-to-peer service that connects oncologists with cancer specialists. The post Color Broadens Cancer Expert Medical Opinion Program appeared first on MedCity News.
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs
Roche’s divarasib was designed offer greater potency and selectivity to KRAS G12C compared to first-generation drugs in this class marketed by Amgen and Bristol Myers Squibb. The Swiss pharma company now plans to submit the data to regulators for review as a potential treatment for non-small cell lung cancer driven by this particular mutated protein….
